Ganeden BC30 Granted GRAS for Infant Formulas
Ganeden says its proprietary probiotic strain is now the first and only spore-forming probiotic allowed to be used specifically in infant formulas.
Photo © iStockphoto.com/tusquare
Ganeden BC30 (Bacillus coagulans GBI-30, 6086) led the pack when it became the first Bacillus strain to receive Generally Recognized As Safe (GRAS) recognition from FDA for use in adult foods and beverages, and now the probiotic strain is making another first. Ganeden (Cleveland) announced last month that its probiotic strain has now become the first and only spore-forming probiotic to be recognized as GRAS for use specifically in infant formulas.
Ganeden explains that a panel of safety experts, including the chair of the Massachusetts General Hospital Department of Pediatrics, and overseen by AIBMR (Seattle), performed the evaluation of the probiotic strain’s enhanced GRAS status. Based on the research on Ganeden BC30, the panel unanimously determined the probiotic should be granted self-affirmed GRAS status. A notification of the GRAS status was then submitted to FDA, which has now issued a “no objections” letter in response to the GRAS notification.
“The safety and efficacy of the Ganeden BC30 strain continues to be undoubtedly proven through solid science, leading to the receipt of numerous domestic and international certifications and approvals,” said Mike Bush, president of Ganeden. “There are few approvals more stringent than those pertaining to infants, and our certification in infant formula speaks highly to the quality and safety of our strain, and the solid foundation of research behind it.”
Ganeden adds that while Ganeden BC30 already appears in more than 550 probiotics foods and beverages worldwide, including many children’s products, the new GRAS notification allows it to be used in infant formulas specifically. As probiotics have become increasing popular in infant products, the firm believes this regulatory approval will open up further formulation opportunities for Ganeden BC30.
“Whether a baby is bottle fed, delivered via C-section, or has to be put on antibiotics, all adversely affect their GI system,” said David Keller, vice president of scientific operations for Ganeden. “It is important to build up the good bacteria, and using a proven probiotic strain like Ganeden BC30 can aid infants in this process.”
Read more:
Probiotic with Protein May Reduce Muscle Damage, Enhance Recovery
2017 Ingredient Trends to Watch for Food, Drinks, and Dietary Supplements: Probiotics
Avocado Smoothies Are the Next Category for Probiotics
Michael Crane
Associate Editor
Nutritional Outlook Magazine
michael.crane@ubm.com
Kratom sees impressive sales growth despite its regulatory status and stigma
March 12th 2025Despite its controversy, kratom is a top-selling ingredient that consumers see value in. That said, brands need to work hard to demonstrate safety and quality of kratom products in the absence of legal regulatory status. Will kratom be able to overcome its stigma for even more growth and consumer acceptance?
DOJ asks Utah court to dismiss FTC lawsuit against Xlear Inc.
March 11th 2025On March 10, the DOJ and the defendant filed a stipulation to dismiss with prejudice the lawsuit in which each party agrees “to be responsible for its own costs and fees and agrees that no party shall be responsible to any other party for any fines, costs, fees, or penalties arising from this case.”
HHS announces efforts to eliminate independent conclusion of GRAS
Published: March 11th 2025 | Updated: March 11th 2025U.S. Department of Health and Human Services (HHS) Secretary, Robert F. Kennedy Jr., is directing the acting U.S. Food and Drug Administration’s (FDA) acting commissioner to explore rulemaking that would eliminate the independent conclusion of GRAS provision.
